ScholarIQanswers from OpenAlex
Novartis Pharma
FunderResearch funding and supported work
Novartis Pharma is a funder indexed in ScholarIQ from OpenAlex.
How many works does Novartis Pharma have?
ScholarIQindexed works
Novartis Pharma has 9,367 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Novartis Pharma?
ScholarIQopenalex
The OpenAlex for Novartis Pharma is on the source record.
What is the ROR of Novartis Pharma?
ScholarIQror
The ROR for Novartis Pharma is on the source record.
What are the most-cited papers on Novartis Pharma?
ScholarIQmost cited works
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt, Lars Køber, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So Young Kim, Faı̈ez Zannad
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff
Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)
Hiroyuki Tsutsui, Hiroshi Ito, Masafumi Kitakaze, Issei Komuro, Toyoaki Murohara, Tohru Izumi, Kenji Sunagawa, Yoshio Yasumura, Masafumi Yano, K. Yamamoto, Tsutomu Yoshikawa, Takayoshi Tsutamoto, Junwei Zhang, Akifumi Okayama, Yoshihiko Ichikawa, Kazuhiro Kanmuri, Masunori Matsuzaki, for the J-EMPHASIS-HF Study Group
Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
Gorana Capkun, Sorcha Corry, Oonagh Dowling, Fatemeh Asad Zadeh Vosta Kolaei, Shweta Takyar, Cláudia Furtado, Páll Jónsson, Diane Kleinermans, Laurie Lambert, Anja Schiel, Karen Facey
Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study
Mitsuru Ohishi, Kazuomi Kario, Tomohiro Katsuya, Tatsuo Shimosawa, Kazuhito Shiosakai, Taketoshi Furugori, Takashi Taguchi, on behalf of the EXCITE-HT investigators